Filtering by Category: diagnostics
The FDA, the Centers for Disease Control and Prevention and the Centers for Medicare and Medicaid Services in the USA have formed an interagency task force with the goal of facilitating rapid development and deployment of in vitro diagnostic tests during public health emergencies.
Sight Diagnostics received the CE Mark last year for its OLO system, which uses digital microscopy to visually analyze cell types by size, shape, count and morphology, from a few drops of blood during a single office visit. The technology has been used to screen over 600,000 samples for malaria infections and will now be adding complete blood count testing to its system. Sight Diagnostics has raised US$27.8 million to continue its global commercial expansion, fund regulatory efforts and support its research and development.
CellMax Life’s CMx platform filters out and counts precancer and cancer cells in the bloodstream. It’s FirstSightCRC test was able to detect the small, precancerous colon polyps known as adenomas with close to 90% accuracy. The increases in cell counts also correlates with increases in disease severity. This is a highly sensitive noninvasive testing option for precancer instead of a colonoscopy.
Contextual Genomics provides assays for detecting genomic mutations in blood and solid tumours. It has released a new version of its Find It solid tumour panel, while its new Follow It panel screens for the same mutations in cell-free circulating tumour DNA found in blood plasma. Follow It can be used to monitor tumour burden, treatment resistance and disease progression.
Liquid biopsy company, Seer, has received $36 million in funding to develop early-warning tests for cancer and neurological diseases. It uses nanotechnology, protein chemistry and machine learning algorithms to profile a broad array of the body’s proteins and generate insights into the progression of diseases at the population level. Seer hopes to collaborate with industry partners to develop new products using this system.
Today, the only way to definitively diagnose Alzheimer's disease in life is through brain scans and tests of cerebrospinal fluid that must be collected via lumbar puncture. Though cumbersome and expensive, such tests provide the most accurate diagnoses for patients. Investigators at Brigham and Women's Hospital are working to develop a blood test that could replace these procedures to accurately diagnose or even predict Alzheimer's disease before symptoms appear.
Walsh and colleagues developed tests capable of detecting different populations of tau fragments in cerebrospinal fluid and blood. The team analyzed five different tests for tau fragments, finding that one, known as the NT1 assay, showed sufficient diagnostic sensitivity (the ability to predict AD cases) and specificity (the ability to exclude controls) to pursue its use as a potential screening tool for Alzheimer's disease. This was confirmed in both sets of patients.
The Apple Watch has a new free software update that allows for wrist-based ECGs on-the-go. Each ECG recording is saved in an iPhone app and can be shared as a PDF with physicians. The watch will also track a person’s pulse in the background and send the wearer a notification if it detects a possible atrial fibrillation, the most common form of irregular heart rhythm.
University of Queensland researchers developed a screening tool to inform clinicians if a patient may have cancer through a simple and inexpensive blood test. However, the procedure does not show where the cancerous cells are located and how serious the patient’s condition is. The test uses gold nanoparticles to detect for cancer DNA and the result is a colour change visible to the naked eye.
MIT researchers have now developed a nanoparticle-based technology that could be used to improve the speed of pneumonia diagnosis. This type of sensor could also be used to monitor whether antibiotic therapy has successfully treated the infection.
The team developed nanoparticles coated with peptides (short proteins) that can be chopped up by certain proteases, such as those expressed by cancer cells. When these particles are injected into the body, they accumulate in tumors, if any are present, and proteases there chop the peptides from the nanoparticles. These peptides are eliminated as waste and can be detected by a simple urine test.
For this study, the researchers delivered the nanoparticles intravenously, but they are now working on a powdered version that could be inhaled.
Screening women for HPV, or human papillomavirus, is a promising way to help detect cervical cancer early, but many at-risk women go without screening for the virus and without Pap tests that look for abnormal cells on the cervix.
A new study from The Ohio State University found that mailing at-home HPV tests to hard-to-reach women may be a viable approach, one that could be especially helpful in regions such as Appalachia, where access to women’s health care can be limited.
The study, which appears in the journal Sexually Transmitted Diseases, found that almost 80 percent of women who received the kits used them and sent them back to the researchers for testing. About a quarter of them tested positive for a cancer-causing type of HPV.